The Effect of Collagen and Fibrin Hydrogels Encapsulated with Adipose Tissue Mesenchymal Stem Cell-Derived Exosomes for Treatment of Spinal Cord Injury in a Rat Model.
Afsartala Z., Hadjighassem M., Shirian S., Ebrahimi-Barough S., Gholami L., Parsamanesh G.
Animal Study with a reported sample of 6 on Spinal Cord Injury, published in Iran J Biotechnol (2023) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Iran J Biotechnol (2023)
- Country
- Iran
- Reported sample size
- 6
- Source database
- PubMed
- PMID
- 38344702
- DOI
- 10.30498/ijb.2023.362229.3505
Abstract (original English)
Mesenchymal stem cell (MSC) derived exosomes (MSC-DE) have been demonstrated to be potential candidates for the treatment of rat spinal cord injury (SCI). The effect of AD-MSC and AD-MSC-DE encapsulated into collagen and fibrin hydrogels on the treatment of SCI in a rat animal model was investigated for introducing a new effective SCI treatment method. The AD-MSC-DE was isolated using ultra-centrifugation at 100,000×g for 120 min and characterized by different methods. Fibrin and collagen hydrogels were synthesized and then mixed with AD-MSC-DE suspension. the characterized AD-MSC-DE were encapsulated into collagen and fibrin hydrogels. eighteen adult male Wister rats were randomly classified into 3 equal groups (n=6): the control group (SCI rat without treatment), SCI rat treated with either AD-MSC-DE encapsulated in collagen hydrogel or encapsulated in fibrin hydrogel groups. the treatment approaches were evaluated using clinical, histological, and molecular assays. The AD-MSC-DE encapsulated into fibrin and collagen groups showed better clinical function than the control group. The AD-MSC-DE encapsulated into fibrin and collagen also improved SCI-induced polio and leuko-myelomalacia and leads to higher expression of NF protein than the control group. In the AD-MSC-DE encapsulated into collagen and fibrin leads to up-regulation the mean levels of NEFL (23.82 and 24.33, respec
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.
Systematic Review on Spinal Cord Injury, Chronic Inflammation, Immune Modulation, published in Cell Transplant (2026) — summary generated from the PubMed abstract.
- 2026
Cell Transplant - Level AMeta-analysisPubMed
Stem cell-derived exosome treatment for acute spinal cord injury: a systematic review and meta-analysis based on preclinical evidence.
Meta-analysis on Spinal Cord Injury, published in Front Neurol (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurol - Level ASystematic ReviewPubMed
Brain-derived neurotrophic factor (BDNF) as biomarker in stem cell-based therapies of preclinical spinal cord injury models: A systematic review.
Systematic Review on Spinal Cord Injury, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
- 2025
Tissue Cell3 citations - Level ASystematic ReviewEurope PMC
Revolutionizing neural regeneration with smart responsive materials: Current insights and future prospects
Systematic Review on Spinal Cord Injury, published in Bioact Mater (2025) — summary generated from the PubMed abstract.
- 2025
Bioact Mater5 citations - Level ASystematic ReviewEurope PMC
Conductive Nanocomposite Hydrogels for Neural Tissue Engineering: A Systematic Scoping Review of Recent Trends
Systematic Review with a reported sample of 42 on Diabetic Foot, Stroke Research, Spinal Cord Injury, Neuroinflammation, published in Adv Sci (Weinh) (2025) — summary generated from the PubMed abstract.
- 2025
- n = 42
Adv Sci (Weinh)18 citations - Level ASystematic ReviewEurope PMC
Emerging regenerative strategies for spinal cord injury: exosome-derived mechanisms and therapeutic insights
Systematic Review on Spinal Cord Injury, Neuroinflammation, published in Front Neurosci (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurosci